NZ756365A - Tissue factor pathway inhibitor antibodies and uses thereof - Google Patents

Tissue factor pathway inhibitor antibodies and uses thereof

Info

Publication number
NZ756365A
NZ756365A NZ756365A NZ75636516A NZ756365A NZ 756365 A NZ756365 A NZ 756365A NZ 756365 A NZ756365 A NZ 756365A NZ 75636516 A NZ75636516 A NZ 75636516A NZ 756365 A NZ756365 A NZ 756365A
Authority
NZ
New Zealand
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Application number
NZ756365A
Other versions
NZ756365B2 (en
Inventor
James R Apgar
Susan Benard
Gregory J Carven
Sunita R Hett
Matthew Holsti
Reema Jasuja
Macy Jin
Zong Sean Juo
Debra Pittman
Mark Stahl
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ756365A publication Critical patent/NZ756365A/en
Publication of NZ756365B2 publication Critical patent/NZ756365B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to antibodies,and antigen-binding fragments thereof,that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.

Claims (28)

What is claimed is:
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope in Kunitz Domain 2 (K2) of Tissue Factor Pathway Inhibitor (TFPI), wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of: (a) an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) comprising a VH complementarity determining region one (CDR-H1) comprising the amino acid sequence of SEQ ID NO:48, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:49 and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:50 and a light chain variable region (VL) comprising a VL complementarity determining region one (CDR-L1) comprising the amino acid sequence of SEQ ID NO:43, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:45; (b) an antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence of SEQ ID NO: 51 and a VL comprising the amino acid sequence of SEQ ID NO: 46; (c) an antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence of SEQ ID NO: 67 and a VL comprising the amino acid sequence of SEQ ID NO: (d) an antibody or antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 47; and (e) an antibody or antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO: 78.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein said epitope comprises residues: Glu100, Glu101, Asp102, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Cys130, Leu131, and Gly132 according to the numbering of SEQ ID NO:2
3. The antibody, or antigen-binding fragment thereof, of claim 1, wherein said antibody, or antigen-binding fragment thereof, binds to TFPI with a binding affinity (Kd) value of from about -8 -10 1x10 M to about 1x10 M.
4. The antibody or antigen-binding fragment thereof of claim 1, wherein said antibody or antigen-binding fragment thereof: (i) decreases clotting time as measured in a plasma based dilute prothrombin time assay; (ii) reduces clotting time in whole blood as measured by thromboelastrography; (iii) increases thrombin generation; (iv) increases FXa activity in the presence of TFPI; (v) enhances platelet accumulation in the presence of TFPI; (vi) increases fibrin generation in the presence of TFPI; or (vii) any combination thereof.
5. The antibody or antigen-binding fragment thereof of claim 4, wherein said plasma or whole blood is deficient in Factor VIII or Factor IX.
6. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the antibody or antigen-binding fragment thereof of claim 1.
7. The nucleic acid of claim 6, wherein the nucleotide sequence encodes a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:48, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:50, and a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:43, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:45.
8. The nucleic acid of claim 7, wherein the nucleotide sequence encodes a VH comprising the amino acid sequence of SEQ ID NO:51 and a VL comprising the amino acid sequence of SEQ ID NO:46.
9. The nucleic acid of claim 7, wherein the nucleotide sequence encodes a VH comprising the amino acid sequence of SEQ ID NO:67 and a VL comprising the amino acid sequence of SEQ ID NO:77.
10. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of claim 1, and a pharmaceutically acceptable carrier or excipient.
11. Use of the antibody or antigen-binding fragment thereof of claim 1 in the manufacture of a medicament for reducing the activity of Tissue Factor Pathway Inhibitor (TFPI).
12. The use of claim 11, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO: 78.
13. Use of the antibody or antigen-binding fragment thereof of claim 1 in the manufacture of a medicament for shortening bleeding time.
14. The use of claim 13 wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO: 78.
15. The use of claim 11, wherein said subject suffers from or is susceptible to hemophilia A, hemophilia B, von Willebrand Disease (vWD), or a platelet disorder.
16. The use of claim 13, wherein said subject suffers from or is susceptible to hemophilia A, hemophilia B, von Willebrand Disease (vWD), or a platelet disorder.
17. The use of claim 11, wherein the medicament is to be administered with a therapeutically effective amount of FVIIa.
18. The use of claim 13, wherein the medicament is to be administered with a therapeutically effective amount of FVIIa.
19. Use of the antibody or antigen binding fragment thereof of claim 1 and a clotting agent in the manufacture of a medicament for shortening bleeding time.
20. The use of claim 19, wherein said subject suffers from or is susceptible to hemophilia A or hemophilia B and said clotting agent is selected from the group consisting of factor VIIa, factor VIII, factor IX and tranexamic acid.
21. The use of claim 20, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO: 78.
22. A vector comprising the nucleic acid molecule of any one of claims 6-9.
23. A host cell comprising the nucleic acid molecule of any one of claims 6-9, or the vector of claim 22, provided that if the cell is a human cell it is ex vivo.
24. The host cell of claim 23, wherein said cell is a mammalian cell.
25. The host cell of claim 24, wherein said host cell is a CHO cell, a HEK-293 cell, or an Sp2.0 cell.
26. A method of making an antibody or antigen-binding fragment thereof, comprising culturing the host cell of any one of claims 23-25, under a condition wherein said antibody or antigen-binding fragment is expressed by said host cell.
27. The method of claim 26, further comprising isolating said antibody or antigen-binding fragment thereof.
28. The antibody or antigen-binding fragment thereof of claim 1, substantially as herein described with reference to any one of the examples and/or
NZ756365A 2016-08-10 Tissue factor pathway inhibitor antibodies and uses thereof NZ756365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207229P 2015-08-19 2015-08-19
US201662360205P 2016-07-08 2016-07-08
NZ739871A NZ739871A (en) 2015-08-19 2016-08-10 Tissue factor pathway inhibitor antibodies and uses thereof

Publications (2)

Publication Number Publication Date
NZ756365A true NZ756365A (en) 2025-02-28
NZ756365B2 NZ756365B2 (en) 2025-06-04

Family

ID=

Also Published As

Publication number Publication date
PE20180556A1 (en) 2018-04-02
CA2939010C (en) 2025-09-16
US20210101998A1 (en) 2021-04-08
US10550200B2 (en) 2020-02-04
US10875929B2 (en) 2020-12-29
TW201718659A (en) 2017-06-01
RU2018104283A3 (en) 2019-09-19
SA518390944B1 (en) 2022-02-08
NZ739871A (en) 2022-05-27
JP7303761B2 (en) 2023-07-05
KR102536303B1 (en) 2023-05-26
BR112018001478A2 (en) 2018-09-18
KR20220136381A (en) 2022-10-07
MX2018002048A (en) 2018-04-13
EP3337827B1 (en) 2026-07-08
IL256913A (en) 2018-03-29
CN114163531B (en) 2025-06-13
US12168698B2 (en) 2024-12-17
KR102068915B1 (en) 2020-01-22
EP4792830A2 (en) 2026-08-19
PH12018500211A1 (en) 2018-08-13
IL256913B (en) 2022-02-01
AU2016307967C9 (en) 2025-02-20
JP6664467B2 (en) 2020-03-13
CN107922506B (en) 2021-11-09
KR102068915B9 (en) 2023-10-12
JP7854307B2 (en) 2026-05-01
KR20230074843A (en) 2023-05-31
CN107922506A (en) 2018-04-17
CA3174958C (en) 2025-05-27
MX2022004834A (en) 2022-05-16
US11634504B2 (en) 2023-04-25
IL289766B1 (en) 2023-06-01
JP2022084623A (en) 2022-06-07
WO2017029583A3 (en) 2017-07-20
US20200190214A1 (en) 2020-06-18
IL289766A (en) 2022-03-01
CO2018001473A2 (en) 2018-05-10
EP3337827A2 (en) 2018-06-27
RU2018104283A (en) 2019-09-19
IL289766B2 (en) 2023-10-01
CN114163531A (en) 2022-03-11
JP2020096627A (en) 2020-06-25
WO2017029583A2 (en) 2017-02-23
AU2022201091A1 (en) 2022-03-10
US20170073428A1 (en) 2017-03-16
CA2939010A1 (en) 2017-02-19
DK3337827T3 (en) 2026-07-27
IL302353A (en) 2023-06-01
KR20180030936A (en) 2018-03-26
KR102438650B1 (en) 2022-08-31
JP2018527922A (en) 2018-09-27
KR20190097319A (en) 2019-08-20
MY195443A (en) 2023-01-21
RU2705540C2 (en) 2019-11-07
US20250145732A1 (en) 2025-05-08
AU2016307967C1 (en) 2023-10-05
CA3174958A1 (en) 2017-02-19
AU2016307967A1 (en) 2018-02-01
PE20240142A1 (en) 2024-02-01
MX391935B (en) 2025-03-21
TWI640538B (en) 2018-11-11
JP2024054266A (en) 2024-04-16
SG10201912817YA (en) 2020-02-27
AU2016307967B2 (en) 2022-02-17
AU2022201091B2 (en) 2025-03-20
ZA201800453B (en) 2018-12-19
US20230416405A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
AU2009279804C1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2017236063B2 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
JP6475679B2 (en) Optimized monoclonal antibody against tissue factor pathway inhibitor (TFPI)
EP3464383B1 (en) Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
CN111386285B (en) Factor X binders that enhance FX activation
JP2022046656A (en) Anti-coagulation factor xi antibodies
RU2018104283A (en) ANTIBODIES AGAINST INHIBITOR WAYS OF TISSUE FACTOR AND THEIR APPLICATION
US20160297892A1 (en) Novel Methods and Antibodies for Treating Coagulapathy
WO2023028501A1 (en) Anti-cd161 antibodies and uses thereof
US9593166B2 (en) Monoclonal antibodies against antithrombin β
AU2018214222B2 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
CA3177329A1 (en) Protein s antibodies, methods of making and uses thereof
NZ756365B2 (en) Tissue factor pathway inhibitor antibodies and uses thereof
RU2024106219A (en) Antibodies against tissue factor pathway inhibitor and their applications
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2013202752B2 (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2013202745B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2026 BY THOMSON REUTERS

Effective date: 20250701